Retatrutide (30mg/vial)

Retatrutide is a next-generation investigational peptide developed to support weight management and metabolic health. Unlike traditional GLP-1 medications, Retatrutide is a triple hormone receptor agonist, activating the GLP-1, GIP, and glucagon receptors simultaneously. This unique mechanism is designed to reduce appetite, increase feelings of fullness, improve glucose regulation, and enhance energy expenditure through increased fat oxidation.

Clinical research has demonstrated promising results, with participants achieving substantial reductions in body weight alongside improvements in several metabolic health markers. By combining appetite suppression with increased calorie expenditure, Retatrutide represents one of the most advanced therapies currently being studied for obesity and related metabolic conditions.

Retatrutide is currently undergoing Phase 3 clinical trials and has not yet been approved by Health Canada or the U.S. FDA for general clinical use. Its safety and effectiveness continue to be evaluated across multiple studies investigating obesity, type 2 diabetes, cardiovascular health, and other metabolic conditions.